Abstract
TO THE EDITOR: In prostate-cancer patients investigated with 18F‐DCFPyL, a second-generation 18F‐labeled prostate-specific membrane antigen ligand, Jansen et al. have recently validated the image-based tumor‐to‐blood ratio (TBR) as an optimal trade‐off between a reliable surrogate for the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
